VieCuri Medisch Centrum

Running trials

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Active, not recruiting

  Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device

  NCT06567054· POROUS GmbH· Source

• Recruiting

  Optimizing Recovery After Reverse Shoulder Arthroplasty With a Personalized Mobile Health Application

  NCT06520085· VieCuri Medical Centre· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

  NCT07260435· Phase 3· Nick Beije· Source

• Recruiting

  Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

  NCT05779631· Radboud University Medical Center· Source

• Active, not recruiting

  Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Borstkanker Onderzoek Groep· Source

• Active, not recruiting

  A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

  NCT04825743· Phase 3· CeleCor Therapeutics· Source

• Enrolling by invitation

  The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)

  NCT06083155· Radboud University Medical Center· Source

• Recruiting

  Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

  NCT06434896· UMC Utrecht· Source

• Active, not recruiting

  FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

  NCT03562572· Zuyderland Medisch Centrum· Source

• Active, not recruiting

  Multicentric Randomised Trial for Resectable Gastric Cancer

  NCT02931890· Phase 2· The Netherlands Cancer Institute· Source

• Active, not recruiting

  A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

  NCT02301286· Phase 3· Leiden University· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Dutch Colorectal Cancer Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Bladder cancer1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· Phase 3· NewAmsterdam Pharma· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Dutch Colorectal Cancer Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Gout5 works · 0 trials